Prime Medicine Inc. (PRME)
2.69
-0.08 (-2.89%)
At close: Jan 14, 2025, 3:59 PM
2.76
2.56%
After-hours Jan 14, 2025, 05:50 PM EST
undefined% (undefined)
| Bid | 2.7 |
| Market Cap | 352.82M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.06 |
| PE Ratio (ttm) | -1.31 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.77 |
| Volume | 601,894 |
| Avg. Volume (20D) | 1,146,827 |
| Open | 2.76 |
| Previous Close | 2.77 |
| Day's Range | 2.63 - 2.84 |
| 52-Week Range | 2.56 - 9.77 |
| Beta | undefined |
About PRME
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2022
Employees 234
Stock Exchange NASDAQ
Ticker Symbol PRME
Website https://www.primemedicine.com
Analyst Forecast
According to 9 analyst ratings, the average rating for PRME stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 401.86% from the latest price.
Buy 88.89%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Prime Medicine Inc. is scheduled to release its earnings on Feb 28, 2025,
before market opens.
Analysts project revenue of $5.23M, reflecting a n/a YoY growth and earnings per share of -0.36, making a -50.00% decrease YoY.
Analysts project revenue of $5.23M, reflecting a n/a YoY growth and earnings per share of -0.36, making a -50.00% decrease YoY.
2 months ago ·
Source
-9.09%
Prime Medicine shares are trading lower after Char...
Unlock content with
Pro Subscription
3 months ago ·
Source
+11.85%
Prime Medicine shares are trading higher after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for the next generation of ex vivo T-cell therapies. Also, it announced that it is focusing its pipeline on a set of high value programs.
